2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strippoli, G. F.M. Articles by Schena, F. P. Search for Related Content PubMed PubMed Citation Articles by Strippoli, G. F.M. Articles by Schena, F. P. Related Collections Related Article

Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials

Giovanni F.M. Strippoli^*,,, Jonathan C. Craig^*,, Carlo Manno and Francesco P. Schena

*Cochrane Renal Group, NHMRC Centre for Clinical Research Excellence in Renal Medicine, The Children’s Hospital at Westmead, University of Sydney, Australia; Department of Emergency and Organ Transplantation, Section of Nephrology, University of Bari, Bari, Italy; and School of Public Health, University of Sydney, Australia

Correspondence to Dr. Giovanni F.M. Strippoli, Centre for Kidney Research, NHMRC Centre for Clinical Research Excellence in renal medicine, Cochrane Renal Group, Locked Bag 4001, The Children’s Hospital at Westmead and the University of Sydney, Westmead, NSW 2145, Australia. Phone: 02-98453088; Fax: 02-98453038; E-mail: gfmstrippoli{at}katamail.com and GiovannS{at}chw.edu.au

Anemia affects almost all patients with chronic kidney disease (CKD), reduces quality of life, and is a risk factor for early death. Higher hemoglobin (Hb) targets have been widely advocated because of data from observational studies showing that higher Hb is associated with improved survival and quality of life, but higher Hb targets may cause access thrombosis and hypertension and are costly. This study aimed to evaluate the benefits and harms of different Hb targets in CKD on the basis of randomized trial evidence. A comprehensive search of the Cochrane Trials Registry, Medline, Embase, and reference lists was performed. Two independent reviewers assessed studies for inclusion criteria and extracted data on all-cause mortality, cardiovascular disease, strokes, hypertension, seizures, hyperkalemia, access thrombosis, and quality of life. Analysis was by a random-effects model, and results are expressed as relative risk (RR) or weighted mean difference with 95% confidence intervals (CI). Nineteen relevant trials were identified. Twelve trials (638 patients) compared use of erythropoietin versus no erythropoietin treatment, and seven trials (2058 patients) compared higher versus lower Hb targets. Compared with Hb values of >130 g/L or more in the CKD population with cardiovascular disease, Hb values of <120 g/L were associated with lower all-cause mortality (RR, 0.84; 95% CI, 0.71 to 1.00). Hb values of 100 g/L or less reduced the risk of hypertension (RR, 0.50; 95% CI, 0.33 to 0.76) but increased the risk of seizures (RR, 5.25; 95% CI, 1.13 to 24.34). From the available trial evidence, in CKD patients with cardiovascular disease, the benefits associated with higher Hb targets (reduced seizures) are outweighed by the harms (increased risk of hypertension and death). There is insufficient data to guide decisions in patients without cardiovascular disease or in the predialysis population.

Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2004 15: 2955-2958. [Full Text] [PDF]

This article has been cited by other articles:

				F. Locatelli, A. Covic, K.-U. Eckardt, A. Wiecek, R. Vanholder, and on behalf of the ERA-EDTA ERBP Advisory Board Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP) Nephrol. Dial. Transplant., November 26, 2008; (2008) gfn653v1. [Full Text] [PDF]

				Y. Furumatsu, Y. Nagasawa, T. Hamano, H. Iwatani, K. Iio, T. Shoji, T. Ito, Y. Tsubakihara, and E. Imai Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan Nephrol. Dial. Transplant., March 1, 2008; 23(3): 984 - 990. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]

				I. Lenga, C. Lok, R. Marticorena, J. Hunter, N. Dacouris, and M. Goldstein Role of Oral Iron in the Management of Long-Term Hemodialysis Patients Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 688 - 693. [Abstract] [Full Text] [PDF]

				P. Barany and H.-J. Muller Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_4): iv10 - iv18. [Abstract] [Full Text] [PDF]

				W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26. [Full Text] [PDF]

				A. K. Singh, L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson, D. Reddan, and the CHOIR Investigators Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease N. Engl. J. Med., November 16, 2006; 355(20): 2085 - 2098. [Abstract] [Full Text] [PDF]

				K. E. Jie, M. C. Verhaar, M.-J. M. Cramer, K. van der Putten, C. A. J. M. Gaillard, P. A. Doevendans, H. A. Koomans, J. A. Joles, and B. Braam Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors Am J Physiol Renal Physiol, November 1, 2006; 291(5): F932 - F944. [Abstract] [Full Text] [PDF]

				S. Amaral, W. Hwang, B. Fivush, A. Neu, D. Frankenfield, and S. Furth Association of Mortality and Hospitalization with Achievement of Adult Hemoglobin Targets in Adolescents Maintained on Hemodialysis J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2878 - 2885. [Abstract] [Full Text] [PDF]

				E. Paoletti and G. Cannella Update on Erythropoietin Treatment: Should Hemoglobin Be Normalized in Patients with Chronic Kidney Disease? J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S74 - S77. [Abstract] [Full Text] [PDF]

				P. A. Sarafidis and G. L. Bakris Level of Kidney Function Determines Cardiovascular Fate After Coronary Bypass Graft Surgery Circulation, February 28, 2006; 113(8): 1046 - 1047. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673